Multiplier Effects and Compensation Mechanisms for Inclusion in Health Economic Evaluation: A Systematic Review
ConclusionWhile our review suggests that compensation mechanisms and multiplier effects may have a significant impact on productivity losses and costs, much remains unclear about their features, valid measurement, and correct valuation. This hampers their current inclusion in economic evaluation, and therefore, more research into both phenomena remains warranted. (Source: PharmacoEconomics)
Source: PharmacoEconomics - August 17, 2023 Category: Health Management Source Type: research
Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom
The objective of this study was to quantify the value of ceftazidime –avibactam for treating gram-negative infections in the UK considering some of these broader value elements unique to antimicrobials.MethodsA previously developed dynamic disease transmission and cost-effectiveness model was applied to assess the value of introducing ceftazidime-avibactam to UK treatment practice in the management of gram-negative hospital-acquired infections in line with the licenced indications for ceftazidime –avibactam. Model inputs were parameterised using sources aligned to the UK perspective.ResultsThe introduction of ceftazidi...
Source: PharmacoEconomics - August 16, 2023 Category: Health Management Source Type: research
Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland
ConclusionsOur model projected nivolumab+ipilimumab to be cost effective for the non-epithelioid subtype but not for all histologies. Substantial discounts for nivolumab+ipilimumab would be necessary to achieve cost effectiveness for all histologies. (Source: PharmacoEconomics)
Source: PharmacoEconomics - August 12, 2023 Category: Health Management Source Type: research
Moving Forward with Taking a Societal Perspective: A Themed Issue on Productivity Costs, Consumption Costs and Informal Care Costs
(Source: PharmacoEconomics)
Source: PharmacoEconomics - August 2, 2023 Category: Health Management Source Type: research
Cost-Effectiveness Analysis of MammaPrint ® to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
ConclusionStandard MammaPrint® testing to guide the use of endocrine therapy in our simulated patient population appears not to be a cost-effective strategy compared with usual care. The cost effectiveness of the test can be improved by reducing the price or preselecting a population more likely to benefit from the test. (Source: PharmacoEconomics)
Source: PharmacoEconomics - August 1, 2023 Category: Health Management Source Type: research
De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis —Modeling Approach and Validation
ConclusionThis is the first CEM in NASH to incorporate the clinical consequences of several comorbidities. The flexible yet standardized framework permits estimation of the cost-effectiveness of NASH interventions in a variety of settings. The model currently includes several assumptions and will be further developed as more relevant data become available. (Source: PharmacoEconomics)
Source: PharmacoEconomics - July 28, 2023 Category: Health Management Source Type: research
Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical Recommendations
ConclusionsSeveral health economics and outcomes research studies did not offer a justification of their approach of handling missing data and some used only a single method without a sensitivity analysis. This systematic literature review highlights the importance of considering the missingness mechanism and including sensitivity analyses when planning, analyzing, and reporting health economics and outcomes research studies. (Source: PharmacoEconomics)
Source: PharmacoEconomics - July 25, 2023 Category: Health Management Source Type: research
Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework
ConclusionsThis framework can provide accurate VOI estimates to guide coverage policies, value-based pricing, and the design of confirmatory trials for AA drugs. (Source: PharmacoEconomics)
Source: PharmacoEconomics - July 25, 2023 Category: Health Management Source Type: research
Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical Recommendations
ConclusionsSeveral health economics and outcomes research studies did not offer a justification of their approach of handling missing data and some used only a single method without a sensitivity analysis. This systematic literature review highlights the importance of considering the missingness mechanism and including sensitivity analyses when planning, analyzing, and reporting health economics and outcomes research studies. (Source: PharmacoEconomics)
Source: PharmacoEconomics - July 25, 2023 Category: Health Management Source Type: research
Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework
ConclusionsThis framework can provide accurate VOI estimates to guide coverage policies, value-based pricing, and the design of confirmatory trials for AA drugs. (Source: PharmacoEconomics)
Source: PharmacoEconomics - July 25, 2023 Category: Health Management Source Type: research
